Guardant Health, Inc. (NASDAQ: GH) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.49 | Insider Own | 3.72% | Shs Outstand | 134.20M | Perf Week | -0.99% |
| Market Cap | 21.84B | Forward P/E | - | EPS next Y | -1.91 | Insider Trans | -17.78% | Shs Float | 128.82M | Perf Month | -2.65% |
| Enterprise Value | 22.46B | PEG | - | EPS next Q | -0.29 | Inst Own | - | Short Float | 8.69% | Perf Quarter | 25.10% |
| Income | -453.00M | P/S | 18.47 | EPS this Y | 8.18% | Inst Trans | - | Short Ratio | 4.18 | Perf Half Y | 79.89% |
| Sales | 1.18B | P/B | - | EPS next Y | 40.29% | ROA | -23.71% | Short Interest | 11.19M | Perf YTD | 59.37% |
| Book/sh | -1.66 | P/C | 20.75 | EPS next 5Y | - | ROE | 211.46% | 52W High | 176.59 -7.82% | Perf Year | 170.53% |
| Cash/sh | 7.85 | P/FCF | - | EPS past 3/5Y | - | ROIC | -29.30% | 52W Low | 53.40 204.83% | Perf 3Y | 316.53% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 29.71% 27.89% | Gross Margin | 65.01% | Volatility | 5.39% 4.53% | Perf 5Y | 28.99% |
| Dividend TTM | - | EV/Sales | 18.99 | EPS Y/Y TTM | 1.97% | Oper. Margin | -39.75% | ATR (14) | 8.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.71 | Sales Y/Y TTM | 60.08% | Profit Margin | -38.33% | RSI (14) | 51.78 | Recom | 2.06 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.03 | EPS Q/Q | -12.50% | SMA20 | -0.36% | Beta | 1.61 | Target Price | 198.73 |
| Payout | 0.00% | Debt/Eq | 8.34 | Sales Q/Q | 44.40% | SMA50 | 1.78% | Rel Volume | 0.44 | Prev Close | 160.98 |
| Employees | 2,498 | LT Debt/Eq | -16.99 | Earnings | Oct 28 | SMA200 | 37.92% | Avg Volume | 2.51M | Price | 162.78 |
| IPO Date | Oct 04, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -18.14% 6.60% | Net Debt/EBITDA | -1.57 | Volume | 1,114,808 | Change | 1.12% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | UBS | Buy | $150 → $225 |
| Sep-08-26 | Initiated | Rothschild & Co Redburn | Buy | $203 |
| Aug-04-26 | Reiterated | Morgan Stanley | Overweight | $175 → $185 |
| Aug-04-26 | Reiterated | Stephens & Co. | Overweight | $99 → $195 |
| Aug-04-26 | Reiterated | Piper Sandler | Overweight | $127 → $193 |
| Jul-31-26 | Reiterated | RBC Capital | Outperform | $185 → $210 |
| Jul-31-26 | Reiterated | Stifel Nicolaus | $130 → $180 | |
| Jul-31-26 | Reiterated | Goldman Sachs | Buy | $185 → $210 |
| Jul-31-26 | Reiterated | Barclays | Overweight | $115 → $200 |
| Jul-31-26 | Reiterated | BTIG | Buy | $190 → $195 |
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,183 | 982 | 739 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 414 | 349 | 290 | — | — | — | — | — | — | |
| Gross Profit | 770 | 633 | 449 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 864 | 706 | 545 | — | — | — | — | — | — | |
| Research and Development | 376 | 364 | 348 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -470 | -437 | -444 | — | — | — | — | — | — | |
| Interest Expense | 4 | 4 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 21 | 24 | 11 | — | — | — | — | — | — | |
| Net Income Before Taxes | -455 | -418 | -435 | — | — | — | — | — | — | |
| Income Taxes | -2 | -1 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | -453 | -416 | -436 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -453 | -416 | -436 | — | — | — | — | — | — | |
| Net Income | -453 | -416 | -436 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.49 | -3.32 | -3.56 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.49 | -3.32 | -3.56 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.49 | -3.32 | -3.56 | — | — | — | — | — | — | |
| EBITDA | -411 | -374 | -390 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 18.16 | 13.00 | 5.08 | — | — | — | — | — | — | |
| Gross Margin | 65.09 | 64.46 | 60.76 | — | — | — | — | — | — | |
| Operating Margin | -39.73 | -44.50 | -60.08 | — | — | — | — | — | — | |
| Net Margin | -38.29 | -42.36 | -59.00 | — | — | — | — | — | — | |
| Shares Outstanding | 132 | 125 | 123 | — | — | — | — | — | — | |
| Market Capitalization | 21,487 | 12,768 | 3,758 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MIGNONE ROBERTO | Director | Aug 21 '26 | Option Exercise | 0.00 | 264 | 0 | 10,010 | Aug 24 |
| Talasaz AmirAli | Co-Chief Executive Officer | Aug 21 '26 | Sale | 169.16 | 37,500 | 6,343,385 | 37,500 | Aug 24 |
| Hidalgo Medina Manuel | Director | Aug 17 '26 | Option Exercise | 0.00 | 232 | 0 | 4,788 | Aug 18 |
| Tariq Musa | Director | Aug 17 '26 | Sale | 156.45 | 116 | 18,148 | 11,316 | Aug 18 |
| Tariq Musa | Director | Aug 15 '26 | Option Exercise | 0.00 | 250 | 0 | 11,432 | Aug 18 |
| Monroe Terilyn J. | Chief People Officer | Aug 12 '26 | Option Exercise | 22.70 | 46,300 | 1,051,163 | 69,279 | Aug 13 |
| Monroe Terilyn J. | Chief People Officer | Aug 12 '26 | Sale | 165.12 | 46,300 | 7,645,218 | 22,979 | Aug 13 |
| Freeman Chris | Chief Commercial Officer | Aug 10 '26 | Option Exercise | 74.09 | 63,605 | 4,712,507 | 128,979 | Aug 11 |
| Freeman Chris | Chief Commercial Officer | Aug 10 '26 | Sale | 169.58 | 63,605 | 10,786,111 | 65,374 | Aug 11 |
| Hidalgo Medina Manuel | Director | Aug 05 '26 | Option Exercise | 32.55 | 950 | 30,922 | 6,256 | Aug 06 |
| Hidalgo Medina Manuel | Director | Aug 05 '26 | Sale | 164.24 | 1,700 | 279,202 | 4,556 | Aug 06 |
| CLARK IAN T | Director | Aug 04 '26 | Option Exercise | 60.63 | 9,088 | 550,998 | 17,155 | Aug 05 |
| CLARK IAN T | Director | Aug 04 '26 | Sale | 158.92 | 14,180 | 2,253,451 | 2,975 | Aug 05 |
| MIGNONE ROBERTO | Director | Jul 21 '26 | Option Exercise | 0.00 | 264 | 0 | 9,746 | Jul 22 |
| Hidalgo Medina Manuel | Director | Jul 17 '26 | Option Exercise | 0.00 | 232 | 0 | 5,306 | Jul 20 |